ETNB News and Press, 89bio Inc. From 12/04/23

2023-12-04 10:54:59 ET More on 89bio 89bio's Low Price Presents An Opportunity 89bio: Risk And Reward Balance In NASH Therapeutics 89bio gains FDA breakthrough status for NASH candidate Seeking Alpha’s Quant Rating on 89bio Historical earnings ...

—Alignment reached on key elements of the NASH development strategy, including accelerated approval pathway for both F4 and F2-F3 NASH patients using histology— —Outcomes trial in F4 cirrhotic NASH patients expected to support full approval across ...

—Data at week 48 demonstrated that treatment with pegozafermin led to sustained statistically significant improvements across liver fat and non-invasive tests (NITs) of liver injury/inflammation and fibrosis in NASH patients with fibrosis stage F2-F3— —Subgroups of ...

SAN FRANCISCO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Manag...

—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic (F4) patients at week 24— —A responder analysis suggests that responses in NITs were correlated with fi...

89bio Inc. (ETNB) is expected to report $-0.5 for Q3 2023

2023-11-08 17:15:44 ET More on 89bio 89bio's Low Price Presents An Opportunity 89bio: Risk And Reward Balance In NASH Therapeutics 89bio gains FDA breakthrough status for NASH candidate 89bio gains as UBS starts at Buy; cites upcoming data from Akero ...

–Pegozafermin granted Breakthrough Therapy Designation (BTD) for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis– –Feedback from regulatory agencies on pegozafermin Phase 3 development program in NASH expected this quarter– ...

2023-10-26 14:15:56 ET Summary 89bio, Inc. stock dropped along with other NASH players after Akero's efruxifermin failed a phase 2 trial. Despite the drop, 89bio remains attractive with excellent phase 2 data and strong financials. 89bio's pegozafermin has shown positive resul...

2023-10-26 01:30:02 ET Summary 89bio shows promise in NASH therapeutics, backed by robust Phase 2b trials of its drug pegozafermin. Financially stable with a significant cash runway, but a sharp YoY increase in operating expenses without a partnership to offset some costs is a con...